What is Schrodinger?
Founded in 1990, Schrodinger specializes in developing sophisticated software solutions that merge physics-based modeling with machine learning. This powerful combination accelerates innovation in drug discovery and materials science, enabling scientific breakthroughs for its partners. The company strategically collaborates with leading entities across the biotechnology, pharmaceutical, chemical, and electronics industries. With a global operational footprint spanning the United States, Europe, Japan, and India, and extending through business partnerships in China and Korea, Schrodinger is well-positioned to serve a diverse international clientele.
How much funding has Schrodinger raised?
Schrodinger has raised a total of $151M across 5 funding rounds:
Other Financing Round
$10M
Other Financing Round
$20M
Other Financing Round
$22M
Unspecified
$85M
Series A
$14M
Other Financing Round (2010): $10M with participation from Cascade Investment
Other Financing Round (2012): $20M led by Bill Gates
Other Financing Round (2015): $22M supported by Scott Becker
Unspecified (2019): $85M featuring Baron, Bill & Melinda Gates Foundation, WuXi AppTec's Corporate Venture Fund, Qiming Venture Partners, Deerfield, and GV
Series A (2020): $14M backed by Andera Partners, Grey Wolf Therapeutics, and Canaan
Key Investors in Schrodinger
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
Qiming Venture Partners
Qiming Venture Partners is a leading investment firm that focuses on identifying and supporting innovative companies in the technology and healthcare sectors. The firm provides strategic capital and operational guidance to help its portfolio companies achieve significant growth and market leadership.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for Schrodinger?
The recent major strategic investment signifies a pivotal moment for Schrodinger, likely enabling the company to further enhance its technology platform, expand its market reach, and deepen its research and development capabilities. This infusion of capital is expected to fuel continued innovation in computational chemistry and materials science, reinforcing Schrodinger's position as a leader in accelerating scientific discovery. The company's focus on critical industries such as pharmaceuticals and materials science suggests a trajectory aimed at addressing complex global challenges through advanced software solutions.
See full Schrodinger company page
